Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. As VP, Clinical Development
ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as VP, Clinical Development. Dr. Eisen is a translational medicine and clinical development specialist with over 20 years of experience in the biotech and pharma sectors.
Prior to joining ITI, Dr. Eisen held executive-level roles in translational medicine for Rexahn Pharmaceuticals, Acorda Therapeutics, Eisai Oncology Product Creation Systems and Daiichi-Sankyo Pharma Development. Prior to that, Dr. Eisen led and managed the drug target discovery and development activities in metabolic diseases for CuraGen Corporation that relied upon functional genomics and proteomics profiling in a long-term collaboration with Bayer, AG. Prior to his industry roles, Dr. Eisen began his career in the academic sector as an Assistant Professor of Pediatrics and Molecular Genetics at the Albert Einstein College of Medicine. Throughout his career, Dr. Eisen has received many academic awards and has been the recipient of numerous research grants. In addition, Dr. Eisen is an author on multiple patents spanning drug targets, gene editing, and predictive biomarkers in cancer research.
“We are delighted to welcome Andrew to the Immunomic team,” said William Hearl, Ph.D., Immunomic Therapeutics’ Chief Executive Officer. “Andrew’s unique translational medicine expertise and deep knowledge of molecular biology will be invaluable to our research and clinical teams as we continue to advance our vaccines into and through the clinic.”
Dr. Eisen holds an A.B. degree from Princeton University and an M.D., Ph.D. in Biophysics from the University of Pennsylvania. He completed his residency at the Children’s Hospital of Philadelphia and is board certified by the American Academy of Pediatrics. Dr. Eisen has an active medical license in the state of Maryland.
ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. ITI’s UNITE platform could potentially have broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics and ITI has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
Latest posts by Chris Frew (see all)
- Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study - November 2, 2021
- Children’s National’s Dr. Kurt Newman Named WBJ’s 2021 CEO of the Year - October 26, 2021
- SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases | Business Wire - October 26, 2021
- Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company | Business Wire - October 21, 2021
- D&D Pharmatech Raises $51M in Series C Financing to Advance Phase 2 Clinical Trials for Neurodegenerative, Fibrotic, and Metabolic Diseases - October 19, 2021